Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today announced two oral
presentations and three poster presentations highlighting data from
non-clinical and clinical studies of deucrictibant at the 13th
C1-inhibitor Deficiency and Angioedema Workshop, being held from
May 4-7, 2023, in Budapest, Hungary.
“Today, two sequential presentations showed how PHVS416
(immediate-release deucrictibant capsules) provided symptom relief
and resolution in the treatment of HAE attacks using the doses
projected through the bradykinin challenge, our in vivo surrogate
marker model,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of
Pharvaris. “The RAPIDe-1 study showed consistent and clinically
meaningful results across all endpoints supporting the further
development of PHVS416 as a potential on-demand therapy for HAE. We
plan to leverage these findings to prepare for RAPIDe-3, our Phase
3 clinical study evaluating PHVS416 for the treatment of on-demand
HAE attacks.”
Anne Lesage, Ph.D., Chief Early Development Officer of
Pharvaris, added, “The outcomes of the cardiovascular assessments
in non-clinical studies, combined with the data from our clinical
studies to date, support the cardiovascular tolerability and safety
profile of deucrictibant for the potential treatment of HAE and
other bradykinin-mediated diseases with unmet need.”
Presentation details and key data highlights include:
- Title: The EC85 Derived from the Oral
Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against
Bradykinin Effects in Healthy Volunteers Predicts the Onset and
Duration of Its Clinical Effects in Hereditary
AngioedemaPresentation ID:
O-18Presenter: Prof. Marcus Maurer, M.D.
Date and Time: Saturday, May 6, 08:45-09:00 CEST
(2:45-3:00 a.m. EDT)A bradykinin challenge model developed in
non-human primates and healthy volunteers was employed to determine
the plasma effective threshold for the bradykinin-antagonistic
properties of deucrictibant in HAE and to predict the duration of
the clinical effects of deucrictibant. Consistent with the modeling
from the bradykinin challenge, a single dose of each of the PHVS416
(immediate-release deucrictibant capsules) doses in the RAPIDe-1
trial reached therapeutic threshold within 15-30 minutes in trial
participants and was maintained for approximately 8-10 hours. In
the same study, rapid onset of PHVS416 clinical effect was
observed, with clinically meaningful improvements within four hours
for all doses. Rescue medication was used for a lower proportion of
PHVS416-treated attacks compared to placebo-treated attacks.
- Title: Efficacy and Safety of the Oral
Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release
Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks:
Topline Results of RAPIDe 1 Phase 2 TrialPresentation
ID: O-19Presenter: Prof. Henriette
Farkas, M.D., Ph.D.Date and Time: Saturday, May 6,
09:00-09:15 CEST (3:00-3:15 a.m. EDT)Analysis of the primary
endpoint of RAPIDe-1 demonstrated that PHVS416 (immediate-release
deucrictibant capsules) significantly reduced attack symptoms at
four hours when compared to placebo, measured as change in the mean
3-symptom composite (skin pain, skin swelling, abdominal pain)
visual analogue scale (VAS-3) score during HAE attacks. All key
secondary efficacy endpoints were also met and participants on
PHVS416 also used substantially less rescue medication compared to
placebo. In the attack-treatment phase, PHVS416 was generally well
tolerated with three treatment-related adverse events (TRAEs)
reported for one PHVS416 30-mg-treated attack and one TRAE reported
for one placebo-treated attack.
- Title: Early symptom relief following
treatment with the oral bradykinin 2 receptor antagonist
deucrictibant immediate-release capsule (PHVS416) in patients with
hereditary angioedema attacksPresentation ID:
P-25Presenter: Prof. Marc A. Riedl,
M.D.Date and Time: Friday, May 5, 14:00-16:00 CEST
(8:00-10:00 a.m. EDT)Improvements in secondary endpoints Mean
Symptom Complex Severity (MSCS, score decreased) and Treatment
Outcome Score (TOS, score increased) during the first four hours
after administration was observed in all three doses of PHVS416
(immediate-release deucrictibant capsules)-treated attacks, as
compared to placebo-treated attacks.
- Title: Cardiovascular safety of the orally
administered bradykinin B2 receptor antagonist, deucrictibant
(PHA121, PHA-022121)Presentation ID:
P-27Presenter: Brigitte Loenders,
Ph.D.Date and Time: Saturday, May 6, 16:00-18:00
CEST (10:00a.m.-12:00 p.m. EDT)The cardiovascular safety of
deucrictibant was assessed in non-clinical studies using in vitro
cardiac ion channel and off-target receptor screenings, and in vivo
acute and chronic studies in non-human primates, a
pharmacologically active species. The occurrence of cardiovascular
events was monitored in Phase 1 and Phase 2 studies of
deucrictibant and continues to be monitored in ongoing and future
clinical studies in HAE. Deucrictibant showed no in vitro alerts
and no effect on cardiovascular function in in vivo non-clinical
studies, and in clinical studies completed to date, including acute
on-demand and repeat administration up to 10 days at anticipated
therapeutic doses.
- Title: Efficacy of the oral bradykinin B2
receptor antagonist deucrictibant immediate-release capsule
(PHVS416) by attack location in the RAPIDe-1 Phase 2 clinical trial
for treatment of hereditary angioedema attacksPresentation
ID: P-38Presenter: Prof. Anna Valerieva,
M.D., Ph.D.Date and Time: Saturday, May 6,
16:00-18:00 CEST (10:00a.m.-12:00 p.m. EDT)Treatment outcomes by
attack location (abdominal and peripheral) were analyzed in
post-hoc analyses of RAPIDe-1. PHVS416 (immediate-release
deucrictibant capsules) demonstrated consistent rapid onset of
symptom relief and resolution of HAE attacks across attack
location. These results are consistent with results of RAPIDe-1
primary analyses.
Additionally, data were presented from an independent
investigator-initiated trial (IIT) in the Netherlands evaluating
deucrictibant as a prophylactic treatment for acquired C1-inhibitor
deficiency. Pharvaris provided PHVS416 (immediate-release
deucrictibant capsules) for this study. Details of the presentation
were:
- Title: Prophylaxis of angioedema attacks due
to acquired C1-Inhibitor deficiency with PHA121, a novel oral
bradykinin B2 receptor antagonistPresentation ID:
O-26Presenter: Remy S. Peterson, M.D.Date
and Time: Saturday, May 6, 11:45-12:00 CEST (5:45-6:00
a.m. EDT)
About RAPIDe-1RAPIDe-1 is a Phase 2,
double-blind, placebo-controlled, randomized, cross-over,
dose-ranging trial of PHVS416 (immediate-release deucrictibant
capsules) for the treatment of HAE type 1 and type 2 (HAE-1/2)
attacks. The trial enrolled participants in Canada, Europe, Israel,
the United Kingdom, and the United States. Eligible participants
were between the ages of 18 and 75 years, diagnosed with HAE type I
or II and experienced three or more attacks in the last four months
or two or more attacks in the last two months prior to screening.
Seventy-four participants were enrolled and 62 of them experienced
147 qualifying HAE attacks that were treated with double-blinded
study drug (either placebo or PHVS416 10, 20, or 30 mg doses).
About PHVS416 (immediate-release deucrictibant
capsules)PHVS416 (immediate-release deucrictibant
capsules) is an investigational medicine intended to treat acute
attacks of hereditary angioedema (HAE) containing deucrictibant, a
highly potent, specific, and orally bioavailable competitive
antagonist of the bradykinin B2 receptor. Pharvaris aims to develop
this formulation to provide rapid and reliable symptom relief,
through rapid exposure of attack-mitigating therapy in a
convenient, small oral dosage form. PHVS416 is currently in Phase 2
clinical development outside the U.S. for the on-demand and
proof-of-concept prophylactic treatment of HAE.
About PHVS719 (extended-release deucrictibant
tablets)PHVS719 (extended-release deucrictibant tablets)
is an investigational medicine intended to prevent attacks of
hereditary angioedema (HAE) containing deucrictibant, a highly
potent, specific, and orally bioavailable competitive antagonist of
the bradykinin B2 receptor. Pharvaris is developing this
formulation to provide sustained exposure of attack-preventing
medicine in a convenient, small oral dosage form. PHVS719 is
currently in Phase 1 clinical development for the prophylactic
treatment of HAE. In healthy volunteers, a single dose of PHVS719
was well tolerated with an extended-release profile supporting
once-daily dosing.
About PharvarisBuilding on its deep-seated
roots in HAE, Pharvaris is a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
HAE attacks. By directly targeting this clinically proven
therapeutic target with novel small molecules, the Pharvaris team
aspires to offer people with all sub-types of HAE safe, effective,
and convenient alternatives to treat attacks, both on-demand and
prophylactically. The company brings together the best talent in
the industry with deep expertise in rare diseases and HAE. For more
information, visit https://pharvaris.com/.
Forward-Looking StatementsThis press release
contains certain forward-looking statements that involve
substantial risks and uncertainties. All statements contained in
this press release that do not relate to matters of historical fact
should be considered forward-looking statements, including, without
limitation, statements relating to our future plans, studies and
trials, and any statements containing the words “believe,”
“anticipate,” “expect,” “estimate,” “may,” “could,” “should,”
“would,” “will,” “intend” and similar expressions. These
forward-looking statements are based on management’s current
expectations, are neither promises nor guarantees, and involve
known and unknown risks, uncertainties and other important factors
that may cause Pharvaris’ actual results, performance or
achievements to be materially different from its expectations
expressed or implied by the forward-looking statements. Such risks
include but are not limited to the following: uncertainty in the
outcome of our interactions with regulatory authorities, including
the FDA with respect to the clinical holds on deucrictibant
clinical trials in the U.S.; the expected timing, progress, or
success of our clinical development programs, especially for
PHVS416 and PHVS719, which are in mid-stage global clinical trials
and are currently on hold in the U.S. as a result of the clinical
holds; risks arising from epidemic diseases, such as the COVID-19
pandemic, which may adversely impact our business, nonclinical
studies, and clinical trials; the expected timing and results of
the rodent toxicology study; the timing of regulatory approvals;
the value of our ordinary shares; the timing, costs and other
limitations involved in obtaining regulatory approval for our
product candidates PHVS416 and PHVS719, or any other product
candidate that we may develop in the future; our ability to
establish commercial capabilities or enter into agreements with
third parties to market, sell, and distribute our product
candidates; our ability to compete in the pharmaceutical industry
and with competitive generic products; our ability to market,
commercialize and achieve market acceptance for our product
candidates; our ability to raise capital when needed and on
acceptable terms; regulatory developments in the United States, the
European Union and other jurisdictions; our ability to protect our
intellectual property and know-how and operate our business without
infringing the intellectual property rights or regulatory
exclusivity of others; our ability to manage negative consequences
from changes in applicable laws and regulations, including tax
laws, our ability to successfully remediate the material weaknesses
in our internal control over financial reporting and to maintain an
effective system of internal control over financial reporting;
changes and uncertainty in general market, political and economic
conditions, including as a result of inflation and the current
conflict between Russia and Ukraine; and the other factors
described under the headings “Cautionary Statement Regarding
Forward-Looking Statements” and “Item 3. Key Information—D. Risk
Factors” in our Annual Report on Form 20-F and other periodic
filings with the Securities and Exchange Commission.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. While Pharvaris may elect to update such
forward-looking statements at some point in the future, Pharvaris
disclaims any obligation to do so, even if subsequent events cause
its views to change. These forward-looking statements should not be
relied upon as representing Pharvaris’ views as of any date
subsequent to the date of this press release.
Contact
Maggie Beller
Head of Public Relations and Communications
maggie.beller@pharvaris.com
Pharvaris NV (NASDAQ:PHVS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Pharvaris NV (NASDAQ:PHVS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024